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ABSTRACT:
Introduction: Thyroid nodule is a common presentation. The estimated prevalence of thyroid nodules is  4-7% by 
clinical examination and 50-60% on ultrasonographic (USG) evaluation. Most are benign without any symptoms or 
cosmetic concerns. Only around 5% are found to be malignant. Methods: This prospective study evaluated  a total 
of 54 patients with thyroid lesions presenting to Otorhinolaryngology, Surgery and Internal Medicine out-patient 
departments of a tertiary hospital  for a period of nine months. The thyroid lesions were categorized into different 
categories using Thyroid Imaging Reporting and Data System (TIRADS) by USG and The Bethesda System for 
Reporting Thyroid Cytopathology (TBSRTC) by fine needle aspiration (FNA). The agreement between TIRADS and 
TBSRTC was evaluated using Cohen's kappa statistics. Results: By FNA, 68.5% were benign lesions whereas 7.4% 
were malignant. Follicular Neoplasm (FN) or Suspicious for FN and Suspicious for Malignancy category comprised 
5.6% each. 1.9% of the lesions showed  Atypia of Unknown Significance (AUS). 11.1% of the lesions were non-
diagnostic or unsatisfactory for evaluation. Overall agreement between the cases by USG and FNA using the TIRADS 
and TBSRTC respectively was 77.77%. There was a substantial agreement between the diagnosis made by these 
systems, kappa (κ)= .633 (95% CI, 0.41 to 0.85, p<0.05). Conclusion: This study observed a substantial agreement 
between the diagnosis made by TIRADS on USG and TBSRTC on FNA. Our study advocates the stratification of 
thyroid lesions according to TIRADS so that only suspicious lesions undergo FNA. 
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INTRODUCTION:
 Thyroid nodule is a common presentation. 
The prevalence of thyroid nodules is estimated to 
be 4-7% by clinical examination and 50-60% on 
ultrasonographic (USG) evaluation.[1,2] Most of 
these nodules are benign without any symptoms or 
cosmetic concerns.[1] Out of these thyroid nodules, 
only around 5% are found to be malignant.[3] 
Therefore, the major concern about thyroid nodule 
is to rule out or confirm malignancy by USG and 
Fine Needle Aspiration (FNA). Surgical removal 
of all thyroid nodules is unnecessary and should be 
stratified by the use of USG and FNA.[4]
 The Bethesda System for Reporting Thyroid 
Cytopathology (TBSRTC) is a standardized, category 
based evaluation of thyroid FNAs to provide a 
uniform diagnostic terminology for pathologists.
[3,5,6] TBSRTC also provides an implied risk of 
malignancy and recommends clinical management 
of the thyroid lesions according to the category.
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[3,4,5] The six diagnostic categories suggested by 
TBSRTC are: I) Non-diagnostic or unsatisfactory; 
II) Benign; III) Atypia of Undetermined Significance 
(AUS) or Follicular Lesion of Undetermined 
Significance (FLUS); IV) Follicular Neoplasm 
(FN) or Suspicious for Follicular Neoplasm; V) 
Suspicious for Malignancy; VI) Malignant.[5]
 The Thyroid Imaging Reporting and Data 
System (TIRADS), first proposed by Horvath et al.[7] 
was established to standardize the scoring system 
of thyroid USG and provide recommendations 
for using FNA and to improve appropriate patient 
management.[4,8,9] The TIRADS categories as 
suggested by American College of Radiology (ACR) 
and known as ACR TI-RADS are: I) Benign; II) Not 
Suspicious; III) Mildly Suspicious; IV) Moderately 
Suspicious; V) Highly Suspicious.[4]
 This study attempts to observe the 
concordance between the TIRADS and TBSRTC on 
thyroid lesions of patients presenting to our hospital.
METHODS:
 This was an observational cross-sectional 
study conducted in the Department of Pathology, 
Lumbini Medical College and Teaching Hospital, 
Palpa, Nepal. We evaluated a total of 54 patients with 
thyroid lesions presenting to the Otorhinolaryngology, 
Surgery and Internal Medicine 0ut-patient 
Departments from March, 2018 to November, 2018 
for a period of nine months. Seven patients who 
were referred to the Pathology Department for FNA 
had not undergone USG evaluation, hence were not 
included in the study.
 Ethical approval was obtained from the 
Institutional Review Committee (IRC-LMC) prior 
to commencement of the study.
 The USG evaluation was done by a single 
radiologist, and the lesion was categorized as per 
TIRADS. If the lesion was primarily evaluated by 
another radiologist, the radiologist (co-investigator) 
categorized the lesion into TIRADS. 
 All the FNAs were performed by either of 
the two pathologists (principal Investigator and 
co-investigator), and the lesions were categorized 
according the TBSRTC. All the cases were reviewed 
by both pathologists. 
 Statistical analysis was done using kappa 
statistics with a 95% confidence, and concordance 
between TIRADS and TBSRTC was evaluated. 
For the purpose of statistical analysis, category I 
was omitted from both TIRADS and TBSRTC, and 
cases of TBSRTC VI category were retained in the 
TBSRTC V as there is no corresponding category 
i.e. TIRADS VI. The categories for analysis were as 
follows:
• TBSRTC II and TIRADS II: “BENIGN”
• TBSRTC III and TIRADS III: “PROBABLY 
BENIGN”
• TBSRTC IV and TIRADS IV: “SUSPICIOUS 
FOR MALIGNANCY”
• TBSRTC V and TIRADS V: “PROBABLY 
MALIGNANT”
All the data management and statistical analysis were 
done using Statistical Package for Social Sciences 
(SPSSTM) software, version 16.
RESULTS:
 We studied a total of 54 patients with thyroid 
lesions presenting to the Department of Pathology 
who underwent USG evaluation.  Age of the patients 
ranged from 17 to 88 years with a mean of 50.74±17.8 
years. 92.6%  were females and 7.4% were males.
Most of the patients presented with Right sided 
thyroid lesion (40.7%) followed by Bilateral 
(31.5%), Left (20.4%), and Midline (4.4%). A 
majority of the lesions were nodular (85.2%), and 
the rest 14.8% were diffuse. The maximum diameter 
of nodular thyroid lesions ranged from 10 to 86 mm 
with a mean of 30.15±15.63 mm by USG.
 By FNA, 68.5% were benign lesions whereas 
7.4% were malignant. Follicular Neoplasm (FN) or 
Suspicious for FN and Suspicious for Malignancy 
category comprised 5.6% each. 1.9% of the lesions 
showed AUS. 11.1% of the lesions were non-
diagnostic or unsatisfactory for evaluation.
The distribution of  TIRADS and TBSRTC categories 
in all thyroid lesions is shown in Figure 1.
 The malignant lesions (TBSRTC-VI) 
comprised 7.4% cases. These cases were revised 
as TBSRTC-V for statistical purpose, as TIRADS 
has no corresponding category and TIRADS-V 
shows the highest risk of malignancy by USG. The 
non-diagnostic or unsatisfactory cases comprising 
11.1% of the cases were omitted from the statistical 
calculations. Overall agreement between the cases 
by USG and FNA using the TIRADS and TBSRTC 
respectively was 77.77%. Cohen’s kappa was run 
to determine the agreement between the TIRADS 
and TBSRTC categories. There was a substantial 
agreement between the diagnosis made by these 
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systems, kappa (κ)= .633 (95% CI, 0.41 to 0.85, 
p<0.05). 
DISCUSSION:
 This study intended to analyze the agreement 
between USG evaluation of thyroid lesions using 
TIRADS and cytological evaluation using TBSRTC. 
Management of thyroid lesions depends on clinical 
history, thyroid function test (TFT), USG and FNA.
[1] FNA is a tool to safely, accurately and cost-
effectively evaluate the thyroid lesions and to decide 
a management protocol.[10,11] However, not all 
thyroid lesions need surgical interventions. Ideally, 
after a clinical evaluation and TFT, USG should be 
performed to stratify the thyroid lesions and FNA 
should be performed only on suspicious lesions.
[12,13,14] 
 Majority of the patients in our study 
were females. Other similar studies also reported 
predominance of female population presenting 
with thyroid lesions.[8,9,12] Increased prevalence 
of thyroid lesions in females, according to studies, 
might be related to hormonal influences of 
estrogen and progesterone. Rate of thyroid nodules 
increases proportionately with ionizing radiation or 
occupational exposures.[13]
 Our study observed 11.1% non-diagnostic 
(ND) or unsatisfactory (USF) i.e. TBSRTC-I cases. 
ND/USF cases range from 1.8% to 23.6% of all thyroid 
FNAs.[3] Thyroid FNAs are ND/USF mostly due 
to cystic nature, sampling error or poor preparation 
techniques. Around 7% of  thyroid lesions will be 
ND/USF even on repeat FNAs.[12,13,14] To reduce 
the chances of false-negative rate, TBSRTC advise 
Diagnostic Category
Risk of 
Malignancy if 
NIFTP≠CA (%)
Risk of 
Malignancy if 
NIFTP=CA (%)
Usual Management
Nondiagnostic or Unsatisfactory 5-10 5-10 Repeat FNA with USG guidance
Benign 0-3 0-3 Clinical and Sonographic follow-up
Atypia of Undetermined Significance 6-18 10-30 Repeat FNA, molecular testing, or lobectomy
Follicular neoplasm or suspicious for 
a follicular neoplasm 10-40 25-40 Molecular testing, lobectomy
Suspicious for malignancy 45-60 50-75 Near-total thyroidectomy or lobectomy
Malignant 94-96 97-99 Near-total thyroidectomy or lobectomy
NIFTP – Noninvasive follicular thyroid neoplasm with papillary-like nuclear features 
CA - Carcinoma
Table 1. Diagnostic Categories with Their Implied Risk of Malignancy, and Recommended Clinical Management
Fig. 1. Distribution of Cases by TIRADS and TBSRTC
 
TIRADS III 
3.7% (2) 
TOTAL CASES = 61 
N = 54 (100%) 
TIRADS II 
85.2% (46) 
TIRADS IV 
1.9% (1) 
TIRADS V 
9.3% (5) 
• TBSRTC I: 11.1% (6) 
• TBSRTC II: 68.5% (37) 
• TBSRTC III: 1.9% (1) 
• TBSRTC IV: 1.9% (1) 
• TBSRTC V: 1.9% (1) 
• TBSRTC IV: 3.7% 
(2) 
• TBSRTC VI: 1.9% 
(1) 
• TBSRTC V: 3.7% (2) 
• TBSRTC VI: 5.6% (3) 
7 cases did not satisfy  
Inclusion criteria 
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that FNA smears should have at least six group of 
well-preserved, well-stained, and well-visualized 
thyroid follicular epithelial cells and each group 
should be composed of ten cells, preferably on a 
single slide.[5,15] Periakaruppan et al.[12] observed 
8% unsatisfactory cases on FNA in their study. The 
implied risk of malignancy on ND/USF is 5-10%, 
as laid down by TBSRTC.[5] However, a systematic 
review shows malignancy rates of 0-26% on follow-
up FNAs.[16] American Thyroid Association (ATA) 
recommends using a USG guidance for repeat FNA 
and correlate with suspicious features on USG. ATA 
suggests that partially cystic nodules yielding ND 
aspirate need close observation or surgical excision, 
whereas surgery should be the considered if lesions 
are solid.[3,14]
 In our study, 7.4% of the cases were 
malignant on FNA. If we include the cases in 
TIRADS-V and TBSRTC-V, the prevalence rate of 
malignant lesions on thyroid is 9.25%, including the 
highly suspicious lesions for malignancy. However, 
no histopathological correlation was made for the 
suspicious lesions on FNA. According to Kilfoy  BA 
et al.[17], thyroid malignancies constitute 1-5% of 
thyroid lesions among women and around 2% in 
men. There is an increasing trend of malignancy 
of thyroid lesions all over the world. This can be 
attributed to the availability of diagnostic facilities.
[18] A capital based study from Nepal by Bista M 
et al.[19] reported a 15.68% prevalence of thyroid 
malignancy on FNA. 
 Overall, our study observed 77.77% 
agreement in diagnosis between TIRADS and 
TBSRTC. Study of Singaporewalla RM et al.[20] 
suggested an agreement of 83% between these two 
systems of thyroid lesion evaluation. In our study, 
there was a substantial agreement between TIRADS 
and TBSRTC as suggested by kappa statistics. 
Similar to our study, Vargas-Uricoechea H et al. 
showed a good concordance between TIRADS and 
TBSRTC.[8] However, these findings of our study 
should be validated by a larger scale study.
 To establish an uniformity in reporting 
purpose and for a clear communication between 
the pathologists and clinicians, TBSRTC has 
proposed different diagnostic categories for thyroid 
lesions on FNA. For each diagnostic category, 
TBSRTC provides implied risk of malignancy and 
recommended clinical management (Table 1).[5]
 TIRADS endorsed by the ACR recommends 
FNA to be performed in lesions which are suspicious 
for malignancy. They have suggested FNA as per the 
TIRADS criteria as follows[4]:
• TIRADS II (Not Suspicious) – No FNA
• TIRADS III (Mildly Suspicious) – FNA if ≥ 
2.5cm, follow-up (F/U) if ≥ 1.5cm
• TIRADS IV (Moderately Suspicious) – FNA if ≥ 
1.5cm, F/U if ≥ 1cm
• TIRADS V (Highly Suspicious) – FNA if ≥ 1cm, 
F/U if ≥0.5cm
CONCLUSION: 
 Our study observed a substantial agreement 
between the diagnosis made by TIRADS on USG 
and TBSRTC on FNA. Thyroid lesions should be 
stratified according to TIRADS and the suspicious 
lesions should only undergo FNA. This protocol will 
be beneficial to avoid unnecessary FNAs on thyroid 
lesions.
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